With a single-quarter revenue surpassing 10 billion yuan and net profit soaring over 178 times year-over-year... Driven by robust realization of innovative value, BEIGENE (688235.SH, 06160, ONC.US) has validated its sustainable profitability through its better-than-expected 2026 Q1 financial report, sending a positive allocation signal to the global capital markets.
High-growth performance validates long-term investment logic. According to reports, BEIGENE recently released its 2026 Q1 results. Under GAAP, the company's global total revenue for Q1 reached $1.513 billion, a 35.5% increase year-over-year, exceeding the FactSet consensus estimate of $1.44 billion. On the profit front, BEIGENE's performance was even more impressive. Data shows the company's operating profit for the period was approximately $250 million, compared to $11 million in the same period last year; net profit for the period was about $227 million, with GAAP diluted earnings per ADS of $1.96. While achieving sustainable innovation revenue and profitability, the company's free cash flow for the period was approximately $161 million, an increase of $173 million compared to the same period last year.
Behind the performance growth is the strong global expansion of BEIGENE's core products. In 2026 Q1, BEIGENE's product revenue reached $1.5 billion, a 34% increase year-over-year. Zanubrutinib (Brukinsa®) global revenue reached $1.1 billion, up 38% year-over-year, continuing its leadership as the global revenue leader in the BTK inhibitor field. Looking at regional market performance, in the U.S. market, Brukinsa® sales for the period reached $761 million, a 35% increase year-over-year, benefiting from strong market demand growth and gains from net pricing. Behind the strong revenue is the product's continued leading position in the CLL indication, achieving market share breakthroughs. In the European market, Brukinsa® also demonstrated strong growth momentum, with sales for the period reaching $182 million, a 51.4% increase year-over-year, driven by continued market share growth in all major European markets, including Germany, Italy, Spain, France, and the UK.
Meanwhile, Tislelizumab (BGB-A317) global sales for the first quarter reached $206 million, a 20% increase year-over-year, maintaining its leading industry position despite intensified competition in China. Approximately half of the revenue growth for Tislelizumab came from markets outside China. Additionally, the company's licensed-in and other products also showed sustained strong momentum, with global sales from Amgen licensed products for the period at $142 million, a 25% increase year-over-year.
Accelerating realization of innovative value. In recent years, while solidifying its leadership in global hematologic oncology treatment, BEIGENE has also been actively shaping a second growth curve in solid tumors, accelerating the realization of its global innovative value. From the perspective of innovative R&D布局, BEIGENE is not limited to a single target or technology platform but is committed to selecting a few disease areas where it has the capability to achieve industry leadership, building a deep and sustainable pipeline.
In hematologic oncology, BEIGENE uses Zanubrutinib as a cornerstone for progressive布局, with Sotorasib (Brukinsa®) being a key anchor point. On May 14, BEIGENE announced that Brukinsa® (Sotorasib, BEQALZI™) received accelerated approval from the FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma who have received at least two prior lines of systemic therapy, including a BTK inhibitor. This marks the first approval of a novel BCL2 inhibitor in the U.S. in ten years, and Sotorasib is currently the only BCL2 inhibitor approved for mantle cell lymphoma in the U.S.
In solid tumors, BEIGENE has formed a commercial/innovative research matrix covering multiple targets and mechanisms, achieving steady progress. For example, Tislelizumab has received priority review designation in the U.S. for the treatment of HER2-positive gastric cancer. Furthermore, the new indication application for Zanidatamab (BGB-A317) in combination with Tislelizumab for first-line treatment of HER2-positive gastroesophageal adenocarcinoma was accepted by China's National Medical Products Administration in April 2026.
It is worth noting that the company's development in solid tumors is also a key focus of Citigroup's latest research report. The report明确指出: BEIGENE's solid tumor projects are transitioning from early to late stages, with key proof-of-concept data for the CDK4 inhibitor, B7-H4 ADC, and GPC3x4-1BB bispecific antibody expected to be presented at the 2026 ASCO annual meeting.
Major financial institutions collectively bullish. Following the disclosure of the above performance, CICC跟进 and issued a latest research report, highlighting BEIGENE's better-than-expected net profit performance in the 2026 Q1 report. The firm maintained its Outperform rating on the company and kept its A/H/US stock target prices at 320 yuan/250 HKD/420 USD, corresponding to potential upside of 29.6%/37.4%/34.1%, respectively.
Citigroup's stance in its report on BEIGENE is even more optimistic. In its latest report dated May 11, Citigroup stated that BEIGENE's Q1 performance was strong, with total revenue 5% higher than its estimate. Management raised the full-year 2026 revenue guidance by $100 million to $6.3-6.5 billion, while maintaining the operating expense guidance, leading to an estimated $50 million increase in operating profit. The bank maintained its "Buy" rating on BEIGENE while further raising its U.S. stock target price from $430 to $453.
In fact, since the beginning of this year, several major domestic and international financial institutions have普遍上调 or maintained high target prices for BEIGENE, driven by a highly consistent logic: focusing on the集中爆发 of BEIGENE's globalization of innovative value realization and commercialization capabilities. The release of the company's 2026 Q1 financial report undoubtedly further strengthens this logic.
Comments